Heidi D. Finnes

1.5k total citations
37 papers, 1.0k citations indexed

About

Heidi D. Finnes is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Heidi D. Finnes has authored 37 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 12 papers in Genetics and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Heidi D. Finnes's work include Cancer Immunotherapy and Biomarkers (13 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Colorectal Cancer Treatments and Studies (8 papers). Heidi D. Finnes is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Colorectal Cancer Treatments and Studies (8 papers). Heidi D. Finnes collaborates with scholars based in United States. Heidi D. Finnes's co-authors include Svetomir N. Markovic, Lisa A. Kottschade, Uma Thanarajasingam, Michael Richter, Roxana Dronca, Anagha Kumar, Yiyi Yan, Sean S. Park, Haidong Dong and Michelle L. Mauermann and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Heidi D. Finnes

32 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Heidi D. Finnes United States 15 693 305 233 224 198 37 1.0k
Juliana Di Iulio Australia 16 645 0.9× 254 0.8× 223 1.0× 103 0.5× 314 1.6× 34 1.1k
Reem Karmali United States 17 559 0.8× 192 0.6× 130 0.6× 160 0.7× 647 3.3× 116 1.0k
Hari Menon India 14 233 0.3× 214 0.7× 189 0.8× 74 0.3× 176 0.9× 73 633
Seongseok Yun United States 18 464 0.7× 248 0.8× 125 0.5× 147 0.7× 206 1.0× 79 1.1k
Geoffrey Chong Australia 15 393 0.6× 179 0.6× 117 0.5× 62 0.3× 307 1.6× 59 769
Julie Chang United States 14 383 0.6× 261 0.9× 176 0.8× 64 0.3× 379 1.9× 44 806
Mihaela Munteanu United States 14 538 0.8× 339 1.1× 107 0.5× 109 0.5× 548 2.8× 61 1.1k
Hirotaka Takasaki Japan 16 244 0.4× 148 0.5× 92 0.4× 131 0.6× 317 1.6× 59 732
Sarah M. Larson United States 14 343 0.5× 200 0.7× 89 0.4× 77 0.3× 201 1.0× 74 749
Gareth P. Gregory Australia 16 495 0.7× 221 0.7× 65 0.3× 144 0.6× 421 2.1× 74 956

Countries citing papers authored by Heidi D. Finnes

Since Specialization
Citations

This map shows the geographic impact of Heidi D. Finnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi D. Finnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi D. Finnes more than expected).

Fields of papers citing papers by Heidi D. Finnes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi D. Finnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi D. Finnes. The network helps show where Heidi D. Finnes may publish in the future.

Co-authorship network of co-authors of Heidi D. Finnes

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi D. Finnes. A scholar is included among the top collaborators of Heidi D. Finnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi D. Finnes. Heidi D. Finnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Finnes, Heidi D., et al.. (2025). Pharmacy leadership: Balancing the roles of colleague and manager. American Journal of Health-System Pharmacy. 82(15). e657–e660.
2.
Chakrabarti, Sakti, Heidi D. Finnes, & Amit Mahipal. (2022). Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management. Expert Opinion on Drug Metabolism & Toxicology. 18(1). 85–98. 14 indexed citations
3.
Parikh, Sameer A., Sara J. Achenbach, Timothy G. Call, et al.. (2020). The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Medicine. 9(10). 3390–3399. 39 indexed citations
4.
Pai, Sara I., R.R. Brodie, Robert W. Carlson, et al.. (2020). Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit. Journal for ImmunoTherapy of Cancer. 8(1). e000112–e000112. 6 indexed citations
5.
McGarrah, Patrick W., Konstantinos Leventakos, Timothy J. Hobday, et al.. (2020). Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma. Pancreas. 49(4). 529–533. 17 indexed citations
6.
Manohar, Sandhya, Ranine Ghamrawi, Lisa A. Kottschade, et al.. (2020). Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy. Kidney360. 1(1). 16–24. 47 indexed citations
7.
Block, Matthew S., Vera J. Suman, Wendy K. Nevala, et al.. (2020). A phase I trial of nab-paclitaxel/bevacizumab (AB160) nano-immunoconjugate therapy for unresectable stage IV malignant melanoma (MM): MC1371 (NCT02020707).. Journal of Clinical Oncology. 38(15_suppl). e22020–e22020. 1 indexed citations
8.
Koehler, Amber B., Nelson Leung, Timothy G. Call, et al.. (2020). Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leukemia & lymphoma. 61(10). 2383–2388. 17 indexed citations
9.
Finnes, Heidi D., et al.. (2020). Factors affecting 48-hour methotrexate levels following high-dose methotrexate (HDMTX) in lymphoma.. Journal of Clinical Oncology. 38(15_suppl). e20033–e20033. 1 indexed citations
10.
Chakrabarti, Sakti, Heidi D. Finnes, Andrea Murányi, et al.. (2019). Intratumoral CD3+ and CD8+ T-cell densities in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC) receiving programmed death-1 (PD-1) blockade.. Journal of Clinical Oncology. 37(15_suppl). 3532–3532. 2 indexed citations
11.
Yan, Yiyi, Anagha Kumar, Heidi D. Finnes, et al.. (2018). Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Frontiers in Immunology. 9. 1739–1739. 182 indexed citations
12.
Chakrabarti, Sakti, Jaskanwal Deep Singh Sara, Ronstan Lobo, et al.. (2018). Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. Clinical Colorectal Cancer. 18(1). 52–57. 29 indexed citations
13.
Finnes, Heidi D.. (2018). Acalabrutinib (Calquence®). Oncology Times. 40(8). 16–16.
14.
Kao, Justin, Bing Liao, Svetomir N. Markovic, et al.. (2017). Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies. JAMA Neurology. 74(10). 1216–1216. 224 indexed citations
15.
Thanarajasingam, Uma, et al.. (2017). SAT0711 Checkpoint inhibitor therapy in patients with advanced malignancies and preexisting rheumatologic disease: the mayo clinic experience. Annals of the Rheumatic Diseases. 76. 1044–1044. 1 indexed citations
16.
Finnes, Heidi D.. (2017). Durvalumab (Imfinzi™). Oncology Times. 39(22). 35–35.
17.
Finnes, Heidi D., et al.. (2016). Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Research. 26(6). 609–615. 49 indexed citations
18.
Felice, Kara M. De, Arjun Gupta, Sagar Rakshit, et al.. (2015). Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Research. 25(4). 321–327. 37 indexed citations
19.
Shanafelt, Tait D., Bijan J. Borah, Heidi D. Finnes, et al.. (2015). Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels. Journal of Oncology Practice. 11(3). 252–258. 79 indexed citations
20.
Kasi, Pashtoon Murtaza, Gita Thanarajasingam, Heidi D. Finnes, et al.. (2015). Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. SHILAP Revista de lepidopterología. 2015. 1–7. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juliana Di Iulio Breakdown of academic impact, for papers by Reem Karmali Breakdown of academic impact, for papers by Hari Menon Breakdown of academic impact, for papers by Seongseok Yun Breakdown of academic impact, for papers by Geoffrey Chong Breakdown of academic impact, for papers by Julie Chang Breakdown of academic impact, for papers by Mihaela Munteanu Breakdown of academic impact, for papers by Hirotaka Takasaki Breakdown of academic impact, for papers by Sarah M. Larson Breakdown of academic impact, for papers by Gareth P. Gregory
Rankless by CCL
2026